Company: PRTA
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001559053-25-000044
Chunk: 36

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 2
Chunk 36
---
 thousands)                                                                                                                
  Collaboration revenue                               $                       2,415      $         970      $           1,445      149  
  Revenue from license and intellectual property      —                                  —                  —                      —    
  Total revenue                                       $                       2,415      $         970      $           1,445      149  

                                                      Nine Months Ended                                        Change                           
                                                      September 30,                                                                             
                                                      2025                              2024                   $                          %     
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  (Dollars in thousands)                                                                                                                        
  Collaboration revenue                               $                      9,613      $         132,984      $           (123,371)      (93)  
  Revenue from license and intellectual property      50                                50                     —                          —     
  Total revenue                                       $                      9,663      $         133,034      $           (123,371)      (93)  

Total revenue was$2.4 million and$1.0 million for the three months ended September 30, 2025 and2024, respectively, and$9.7 million and $133.0 million for the nine months ended September 30, 2025, and 2024, respectively.

Collaboration revenue was$2.4 million and$9.6 million for the three and nine months ended September 30, 2025, compared to$1.0 million and$133.0 million for the three and nine months ended September 30, 2024. Collaboration revenue for three and nine months endedSeptember 30, 2025 was related to the partial performance of our PRX019 Phase 1 Clinical Trial Obliga tion. Collaboration revenue of$133.0 million fo r the nine months ended September 30, 2024 included $107.9

million from the PRX019 Global License Agreement and PRX019 Phase 1 Clinical Trial Obligation and $25.0 million was related to BMS’s material rights for the US Rights and Global Rights for the TDP-43 Collaboration Target that expired unexercised on May 24, 2024 as a result of the expiration of the research term of the Collaboration Agreement.

As of September 30, 2025, the Company has$2.7 million of deferred revenue related to the remaining performance obligations under the PRX019 Global License Agreement related to PR